Table 2. Outcomes of the Included Studies.
| Study | Antibodies outcome | Follow up period | Dose | Patients receiving dialysis | Participants not receiving dialysis | ||
|---|---|---|---|---|---|---|---|
| No. | Responders, No. (%) | No. | Responders, No. (%) | ||||
| Agur et al,17 2021 | Anti-S IgG | 2-6 wk | 2 | HD: 122 ; PD: 23 | HD: 114 (93.4); PD: 22 (95.7) | 0 | NA |
| Anand et al,32 2021 | Anti-RBD IgG | 2-4 wka | 2 | 610 | 474 (77.7) | 0 | NA |
| Attias et al,6 2021 | Anti-S IgG | 3 wk | 2 | 64 | 55 (85.9) | 0 | NA |
| 4 wk | 1 | 69 | 23 (33.3) | ||||
| Bertrand et al,26 2021 | Anti-S IgG | 4 wk | 2 | 9 | 8 (88.9) | 0 | NA |
| 3 wk | 1 | 9 | 1 (11.1) | ||||
| Billany et al,7 2021 | Anti-RBD IgG | 4 wk (mean 27.8 d) | 1 | 95 | 75 (79.8) | 0 | NA |
| Broseta et al,8 2021 (mRNA-1273) | Anti-RBD IgG | 3 wk | 2 | 100 | 98 (98) | 0 | NA |
| Broseta et al,8 2021 (BNT162b2) | Anti-RBD IgG | 3 wk | 2 | 75 | 69 (92) | 0 | NA |
| Chan et al,27 2021 | Anti-RBD IgG | 1 wk | 2 | 61 | 58 (95.1) | 0 | NA |
| Clarke et al,33 2021 | Anti-S IgG | 5-6 wk (median 39-41 d)b | 2 | 1020 | 938 (92) | 0 | NA |
| Danthu et al,10 2021 | Anti-S IgG | 36 d | 2 | 79 | 59 (78.7) | 7 | 7 (100) |
| Duarte et al,34 2021 | Anti-S IgG | 3 wk | 2 | HD: 42; PD: 25 | HD: 36 (85.7); PD: 25 (100) | 0 | NA |
| 1 | HD: 42; PD: 25 | HD: 21 (50); PD: 22 (88) | 0 | NA | |||
| Ducloux et al,14 2021 | Anti-RBD IgG | NR | 2 | 45 | 40 (88.9) | 0 | NA |
| Ducloux et al,14 2021 | Anti-RBD IgG | NR | 3 | 45 | 42 (93.3) | 0 | NA |
| Frantzen et al,28 2021 | Anti-S IgG | 4 wk | 2 | 244 | 221 (90.6) | 0 | NA |
| Frantzen et al,15 2021 (3rd boost dose cohort) | Anti-S IgG | 4 wk | 3 | 88 | 86 (97.7) | 0 | NA |
| Goupil et al,11 2021 | Anti-RBD IgG | 4 wk | 1 | SARS-CoV-2 naive: 131; previous infection: 19 | SARS-CoV-2 naive: 75 (57.3); previous infection: 16 (84.2) | 0 | NA |
| Grupper et al,20 2021 | Anti-RBD IgG | 30 d (median) | 2 | 56 | 54 (96.5) | 95 | 95 (100) |
| Lacson et al,29 2021 | Anti-RBD IgG | 2 wk | 2 | 186 | 165 (88.7) | 0 | NA |
| Jahn et al,22 2021 | Anti-S IgG | 2 wk | 2 | 72 | 67 (93.1) | 16 | 16 (100) |
| Lensy et al,12 2021 | Anti-S IgG | 2 wk | 1 | 27 | 8 (29.6) | 14 | 8 (57.1) |
| Longlune et al,16 2021 | Anti-S IgG | 4 wk | 2 | HD: 78; PD: 20 | HR: 64 (82.1); PD: 17 (85) | 0 | NA |
| 4 wk | 1 | HD: 80; PD: 24 | HD: 17 (21.3); PD: 10 (41.7) | 0 | NA | ||
| 1 mo | 3 | HD: 77 | 69 (89.6) | 0 | NA | ||
| Rincon-Arevalo et al,21 2021 | Anti-S IgG | 1 wk | 2 | 44 | 31 (70.5) | 25 | 25 (100) |
| RodrÃguez-Espinosa et al,19 2021 | Anti-RBD IgG | 3 wk | 2 | 32 | 31 (96.9) | 0 | NA |
| 4 wk | 1 | 32 | 20 (62.5) | 0 | NA | ||
| Sattler et al,25 2021 | Anti-S IgG | 8 d | 2 | 26 | 22 (84.6) | 39 | 39 (100) |
| Schrezenmeier et al,18 2021 | Anti-S IgG | 3-4 wk | 2 | 36 | 32 (88.9) | 44 | NR |
| Simon et al,30 2021 | Anti-RBD | 3 wk | 2 | 81 | 59 (72.8) | 80 | 80 (100) |
| Speer et al,23 2021 | Neutralizing antibodies | 20 d (median) | 2 | 22 | 14 (62.6) | 46 | 46 (100) |
| 18 d (median) | 1 | 22 | 4 (18.2) | 46 | 43 (93.5) | ||
| Strengert et al,35 2021 | Anti-S IgG | 3 wk | 2 | 81 | 77 (95.1) | 34 | NR |
| Torreggiani et al,13 2021 | Anti-S IgG | 3 wk | 1 | 95 | 35 (36.8) | 0 | NA |
| Weigert et al,36 2021 | Anti-S IgG | 3 wk | 2 | 143 | 130 (91.0) | 143 | 136 (95.1) |
| NA | 1 | 143 | 42 (29.4) | 143 | 71 (49.7) | ||
| Yanay et al,24 2021 | Anti-S IgG | 3-5 wk | 2 | 160 | 144 (90) | 132 | 132 (100) |
| Yau et al,37 2021 (2 dose cohort) | Anti-RBD IgG | 2 wk | 2 | 72 | 63 (87.5) | 35 | 35 (100) |
| 3 wk | 1 | 76 | 31 (40.8) | 0 | NA | ||
| Yau et al,37 2021 (1 dose cohort) | Anti-RBD IgG | 4 wk | 1 | 66 | 33 (50) | 0 | NA |
| Yi et al,5 2021 | Anti-S IgG | NR | 2 | 31 | 26 (83.9) | 0 | NA |
| Zitt et al,31 2021 | Anti-S IgG | 4 wk | 2 | 47 | 46 (97.9) | 0 | NA |
| 4 wk | 1 | 50 | 21 (42) | 0 | NA | ||
Abbreviations: HD, hemodialysis; IgG, immunoglobin G; PD, peritoneal dialysis; NA, not applicable; NR, not reported; RBD, receptor-binding domain.
a
2 Weeks (mRNA), >2 weeks (JNJ-78436735), Median, 29 days.
b
Vaccine interval was NR in prior SARS-CoV-2 infection population.